<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615885</url>
  </required_header>
  <id_info>
    <org_study_id>LMS/PGT/UH/02843</org_study_id>
    <nct_id>NCT03615885</nct_id>
  </id_info>
  <brief_title>Acute Cardio-metabolic Responses to Montmorency Tart Cherry Supplementation in Metabolic Syndrome Patients</brief_title>
  <official_title>Acute Cardio-metabolic Responses to Different Forms of Montmorency Tart Cherry Supplementation in Humans With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hertfordshire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hertfordshire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study examined the effect of Montmorency tart cherry juice and capsules on
      functional and blood-based cardio-metabolic markers in humans with Metabolic Syndrome.
      Participants received a single bolus of Montmorency tart cherry juice, Montmorency tart
      cherry capsules and placebo in a random, crossover trial. Outcome variables were measured
      immediately pre- and up to 5 hours post-bolus. It was hypothesised that Montmorency tart
      cherry juice and capsules would improve cardio-metabolic markers. Furthermore, it was
      hypothesised that Montmorency tart cherry capsules would be more beneficial than Montmorency
      tart cherry juice due to increased bioavailability of phytochemicals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fasting Insulin</measure>
    <time_frame>Pre-Bolus and Post-Bolus (1hr, 3hr, 5hr)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fasting Lipid Profile (Total Cholesterol, HDL, Triglycerides, LDL)</measure>
    <time_frame>Pre-Bolus and Post-Bolus (1hr, 3hr, 5hr)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>Pre-Bolus and Post-Bolus (1hr, 3hr, 5hr)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Augmentation Index</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Measure of arterial stiffness and central blood pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aortic Systolic and Diastolic Pressure</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Measure of arterial stiffness and central blood pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Augmentation Pressure</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Measure of arterial stiffness and central blood pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Output</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Beat-to-beat resting cardiac haemodynamics (cardiac output, mean arterial pressure, strove volume, total peripheral resistance, heart rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stroke Volume</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Beat-to-beat resting cardiac haemodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Beat-to-beat resting cardiac haemodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Arterial Pressure</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Beat-to-beat resting cardiac haemodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Peripheral Resistance</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Beat-to-beat resting cardiac haemodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Resting Energy Expenditure</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Measured from indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Respiratory Quotient</measure>
    <time_frame>Pre-Bolus and Post-Bolus (30min, 1hr, 2hr, 3hr, 4hr, 5hr)</time_frame>
    <description>Measured from indirect calorimetry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo Drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montmorency Tart Cherry Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montmorency Tart Cherry Juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-bolus of Montmorency tart cherry juice (130 mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Montmorency Tart Cherry Capsules</intervention_name>
    <description>Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.</description>
    <arm_group_label>Montmorency Tart Cherry Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Montmorency Tart Cherry Juice</intervention_name>
    <description>100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.
Concentrate contains no sweeteners, preservatives, flavourings or added sugar.</description>
    <arm_group_label>Montmorency Tart Cherry Juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>130ml serving
Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml).</description>
    <arm_group_label>Placebo Drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoker,

        Meet 3 of 5 criteria for Metabolic Syndrome based on National Cholesterol Education
        Program-Adult Treatment Panel III guidelines:

          1. Waist Circumference: &gt;102cm (men), &gt;88cm (women)

          2. Fasting Serum Triglycerides: ≥1.69 mmol.L-1

          3. Fasting High Density Lipoprotein: &lt;1.03 mmol.L-1 (men), &lt;1.29 mmol.L-1 (women)

          4. Blood Pressure: ≥130 mmHg SBP or ≥85 mmHg DBP

          5. Fasting Plasma Glucose: ≥6.1 mmol.L-1

        Exclusion Criteria:

          -  Current or previous history of gastrointestinal, cardiovascular, hepatic or renal
             disease, currently diagnosed with diabetes or uncontrolled hypertension (≥160/100
             mmHg), allergy to maltodextrin or specific fruit products and those currently taking
             medication (such as steroids, NSAIDs, antibiotics, antihypertensive, hypoglycaemic,
             lipid-lowering drugs) or currently using any nutritional or antioxidant supplement.
             Heavy alcohol consumption (&gt;14 units per week).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Hertfordshire</name>
      <address>
        <city>Hatfield</city>
        <zip>AL10 9AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hertfordshire</investigator_affiliation>
    <investigator_full_name>Terun Desai</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>Montmorency Tart Cherry</keyword>
  <keyword>Anthocyanins</keyword>
  <keyword>Polyphenols</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Lipid Profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

